A
Andrea Lampis
Researcher at Institute of Cancer Research
Publications - 130
Citations - 3746
Andrea Lampis is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 21, co-authored 53 publications receiving 2517 citations. Previous affiliations of Andrea Lampis include The Royal Marsden NHS Foundation Trust & University of Milan.
Papers
More filters
Journal ArticleDOI
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Georgios Vlachogiannis,Somaieh Hedayat,Alexandra Vatsiou,Yann Jamin,Javier Fernández-Mateos,Khurum Khan,Khurum Khan,Andrea Lampis,Katherine Eason,Ian Said Huntingford,Rosemary Burke,Mihaela Rata,Dow-Mu Koh,Dow-Mu Koh,Nina Tunariu,Nina Tunariu,David J. Collins,Sanna Hulkki-Wilson,Chanthirika Ragulan,Inmaculada Spiteri,Sing Yu Moorcraft,Ian Chau,Sheela Rao,David Watkins,Nicos Fotiadis,Maria Antonietta Bali,Maria Antonietta Bali,Mahnaz Darvish-Damavandi,Hazel Lote,Hazel Lote,Zakaria Eltahir,Elizabeth C Smyth,Ruwaida Begum,Paul A. Clarke,Jens C. Hahne,Mitchell Dowsett,Johann S. de Bono,Paul Workman,Anguraj Sadanandam,Matteo Fassan,Owen J. Sansom,Suzanne A. Eccles,Naureen Starling,Chiara Braconi,Chiara Braconi,Andrea Sottoriva,Simon P. Robinson,David Cunningham,Nicola Valeri,Nicola Valeri +49 more
TL;DR: Responses to anticancer agents ex vivo in organoids and PDO-based orthotopic mouse tumor xenograft models with the responses of the patients in clinical trials are compared to suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.
Journal ArticleDOI
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
Francesco Perrone,Andrea Lampis,Marta Orsenigo,M. Di Bartolomeo,Arpine Gevorgyan,Marco Losa,Milo Frattini,C Riva,Salvatore Andreola,Emilio Bajetta,Lucio Bertario,Ermanno Leo,Marco A. Pierotti,Silvana Pilotti +13 more
TL;DR: Patients carrying KRAS mutations or with activated PI3K profiles can benefit from targeted treatments only by switching off molecules belonging to the downstream signalling of activated EGFR, such as mammalian target of rapamycin.
Journal ArticleDOI
MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer
Nicola Valeri,Chiara Braconi,Pierluigi Gasparini,Claudio Murgia,Andrea Lampis,Viola Paulus-Hock,Jonathan R. Hart,Lynn Ueno,Sergei I. Grivennikov,Francesca Lovat,Alessio Paone,Luciano Cascione,Khlea M. Sumani,Angelo Veronese,Muller Fabbri,Stefania Carasi,Hansjuerg Alder,Giovanni Lanza,Roberta Gafà,Mary P. Moyer,Rachel A. Ridgway,Julia B. Cordero,Gerard J. Nuovo,Wendy L. Frankel,Massimo Rugge,Matteo Fassan,Joanna Groden,Peter K. Vogt,Michael Karin,Owen J. Sansom,Carlo M. Croce +30 more
TL;DR: Inhibition of miR-135b in CRC mouse models reduces tumor growth by controlling genes involved in proliferation, invasion, and apoptosis and is identified as a key downsteam effector of oncogenic pathways and a potential target for CRC treatment.
Journal ArticleDOI
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial
Elizabeth C Smyth,Matteo Fassan,David Cunningham,William H. Allum,Alicia Okines,Andrea Lampis,Jens C. Hahne,Massimo Rugge,Clare Peckitt,Matthew Nankivell,Ruth Langley,Michele Ghidini,Chiara Braconi,Andrew Wotherspoon,Heike I. Grabsch,Nicola Valeri +15 more
TL;DR: In this article, the authors evaluated whether pathologic response and lymph node status after neoadjuvant chemotherapy are prognostic in patients treated in the MAGIC trial, and compared the results using the Kaplan-Meier method and the log-rank test.
Journal ArticleDOI
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.
Khurum Khan,Khurum Khan,David Cunningham,Benjamin Werner,Georgios Vlachogiannis,Inmaculada Spiteri,Timon Heide,Javier Fernandez Mateos,Alexandra Vatsiou,Andrea Lampis,Mahnaz Darvish Damavandi,Hazel Lote,Ian Said Huntingford,Somaieh Hedayat,Ian Chau,Nina Tunariu,Giulia Mentrasti,Francesco Trevisani,Sheela Rao,Gayathri Anandappa,Gayathri Anandappa,David Watkins,Naureen Starling,Janet Thomas,Clare Peckitt,Nasir Khan,Massimo Rugge,Ruwaida Begum,Blanka Hezelova,Annette Bryant,Thomas Jones,Paula Proszek,Matteo Fassan,Jens C. Hahne,Mike Hubank,Chiara Braconi,Chiara Braconi,Andrea Sottoriva,Nicola Valeri,Nicola Valeri +39 more
TL;DR: This study demonstrates how integrating frequently sampled longitudinal liquid biopsies with a mathematical framework of tumor evolution allows individualized quantitative forecasting of progression, providing novel opportunities for adaptive personalized therapies.